Background. Detection of antiretroviral (ARV) resistance in HIV-infected individuals is not uncommon and may be particularly problematic in HIV-infected pregnant women as it can lead to infant infection with resistant strains. To better evaluate the effect of drug resistance mutations (DRMs) on HIV mother-to-child transmission (MTCT), we determined the prevalence of DRMs in a subset of mother-infant pairs enrolled in a multi-center trial of infant prophylaxis among women not receiving ARVs during the current pregnancy.
Methods. A case-control design of 1:4 (1 transmitter to 4 nontransmitters) was utilized to evaluate ARV resistance as a predictor of HIV MTCT in specimens obtained from mother-infant pairs. Secondary objectives included identification of potential risk factors associated with the presence of DRMs. Viroseq HIV-1 Genotyping System was performed on mother-infant specimens to assess for mutations that might result in a substantial reduction in drug susceptibility and clinical outcome, as determined by the Stanford HIV Drug Resistance Database.
Results. One hundred and forty infants were infected. Of these, 123 HIV infected mother-infant pairs and 483 of 560 women who did not transmit HIV had amplifiable HIV nucleic acid enabling ARV resistance testing. A wide variety of DRMs were detected (Figure 1 ). Sixty (10%) of 606 women had clinically relevant DRMs; 12 (2%) had DRMs against more than 1 ARV class. Among 123 HIV− infected infants, 13 (11%) had clinically relevant DRMs with 3 (2%) harboring DRMs against more than 1 ARV class. Of 13 infants with DRMs, 10 (77%) were infected in utero. In univariate and multivariate analyses, DRMs in mothers were not associated with increased risk of HIV MTCT (AOR 0.79, 95% CI 0.38-1.5). Log HIV viral load was the only predictor of MTCT (OR 1.4, 95% CI 1.2−1.6). The presence of DRMs in mothers who transmitted was strongly associated with the presence of DRMs in infants (P < 0.001).
Conclusion. In infected pregnant women without ARV exposure during their current gestation, the presence of pre-existing DRMs with a wide diversity was noted. DRMs do not increase the risk of HIV MTCT. However, if women with DRMs are not virologically suppressed they are likely to transmit resistant mutations even without selective ARV pressure, thus complicating treatment options.
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No reported disclosures. Background. PrEP, regular use of antiretroviral medications by HIV-negative individuals to prevent new HIV infections, has not been widely adopted by some young, highrisk populations. This study investigated the characteristics and estimated percentage of newly diagnosed HIV-infected individuals in South Carolina (SC) who had visited a health care facility (HCF) while HIV-negative and missed opportunities for initiating PrEP.
Missed Opportunities to
Methods. We used a unique person-level identifier to link case reports from the SC enhanced HIV/AIDS Reporting System and records from a statewide all payer HCF database. The HCF data include inpatient (IP), outpatient (OP), and emergency department (ED) visits to SC facilities. Because the Food and Drug Administration approved PrEP in 2012, we analyzed data for individuals diagnosed with HIV during January 2013-September 2016 with initial CD4 count ≥500 cells (recent infection) and HC visits during 2011 through the date of diagnosis. We used the two-tailed chi-square statistics with a significant threshold of P < 0.05 in SAS to investigate the association between the absence of a PrEP prescription and patient factors including demographics, behavioral risk, visit setting (IP, OP or ED), frequency of previous visits, and residence at diagnosis.
Results. A total of 785 patients were diagnosed with recent HIV infections (initial CD4 ≥500 cell) during January 2013-September 2016. Of these, 504 (64.2%) visited an SC HCF at least once before being diagnosed, 72.4% were males, 52.4% aged <30 years, 54% were men who have sex with men (MSM) or injection drug users (IDU) and 70.2% resided in urban areas. Mean number of HCF visits before HIV diagnosis was 6.6; 84.3% had ED visits; 5.9% had IP visits; and 7.0% had OP visits. Persons of female sex, Black race, younger age and urban residence were more likely to access HCF visit before HIV diagnosis (P < 0.05).
Conclusion 
